On-Demand Webinar

Physiologically-Based Pharmacokinetic Modeling & Simulation to Support Asciminib NDA Submission & Inform Drug Product Label

Physiologically based pharmacokinetic (PBPK) modeling and simulation has become an established approach to assess drug-drug…

CertaraJanuary 13, 2023

Blog

New FDA Validator Rules V1.6 Explained

In this blog, we explore what you need to know about the update to the…

CertaraJanuary 12, 2023

Video

Simcyp Secondary Intelligence Software

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 Introducing Secondary Intelligence. The first and only evidence based quantitative technology for managing off…

CertaraJanuary 10, 2023

Announcement

Certara Awarded NIH Contract for Toxicology Consulting Support

Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system…

CertaraJanuary 10, 2023

Video

If your drug is a CYP3A substrate, we have good news for you!

CertaraJanuary 9, 2023

Announcement

Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme

PRINCETON, N.J., January 9, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,…

CertaraJanuary 9, 2023

Press Release

Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation

Certara improves software capabilities by expanding into deep learning and data fabric PRINCETON, N.J.— January…

CertaraJanuary 4, 2023

White Paper

Drug interactions with therapeutic proteins, regulatory expectations and modeling and simulation approaches

CertaraJanuary 3, 2023

Blog

New FDA Requirement to Support Labeling on DDIs in the Pediatric Population

The effects of drug-drug interactions (DDIs) could differ in the pediatric population compared to adults.…

CertaraDecember 21, 2022

Blog

The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs

Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform can revolutionize your pharmaceutical organization’s approach to PK/PD…

CertaraDecember 16, 2022

Physiologically-Based Pharmacokinetic Modeling & Simulation to Support Asciminib NDA Submission & Inform Drug Product Label

New FDA Validator Rules V1.6 Explained

Simcyp Secondary Intelligence Software

Certara Awarded NIH Contract for Toxicology Consulting Support

If your drug is a CYP3A substrate, we have good news for you!

Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme

Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation

Drug interactions with therapeutic proteins, regulatory expectations and modeling and simulation approaches

New FDA Requirement to Support Labeling on DDIs in the Pediatric Population

The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs

Newsletter sign up

Quick links

Solutions

Contact